Lenalidomid Teva (Lenalidomide)

Lenalidomide is used in hematologic malignancies and related disorders, targeting abnormal plasma cells and lymphoid proliferation.

• Multiple myeloma: reduces disease progression and improves survival in adult patients.
• Mantle cell lymphoma: contributes to tumor control in relapsed or refractory disease.
• Myelodysplastic syndromes with 5q deletion: induces transfusion independence and cytogenetic response.
• Follicular lymphoma: used in combination regimens to achieve remission in certain cases.

• Lenalidomide binds to the cereblon subunit of the CRL4‑E3 ubiquitin ligase complex, altering its substrate specificity. This interaction promotes ubiquitination and proteasomal degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), leading to modulation of cytokine production, enhanced T‑cell and natural killer cell activity, and inhibition of angiogenesis and tumor cell proliferation. The downstream effects result in reduced survival signals for malignant cells and restoration of immune surveillance.

Lenalidomide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Fatigue: persistent tiredness that may affect daily activities.
• Diarrhea: frequent loose or watery stools, sometimes accompanied by abdominal cramping.
• Rash: skin redness, itching, or mild irritation that may appear on the trunk or limbs.
• Constipation: difficulty passing stools, sometimes accompanied by abdominal discomfort.

Serious or Rare Side Effects

• Thromboembolic events: formation of blood clots such as deep‑vein thrombosis or pulmonary embolism, which can be life‑threatening.
• Severe neutropenia: markedly reduced neutrophil count leading to heightened susceptibility to infections.
• Stevens‑Johnson syndrome: a severe, potentially life‑threatening skin reaction characterized by blistering and mucosal involvement.

When prescribing Lenalidomid Teva, several precautions should be observed to minimize risks and ensure safe use.

• Pregnancy contraindication: product is classified Category X and must not be used during pregnancy.
• Thromboembolic risk: assess patient history and consider prophylactic anticoagulation when risk factors are present.
• Hematologic monitoring: perform regular complete blood counts to detect neutropenia or anemia.
• Renal impairment: adjust therapy and monitor kidney function in patients with reduced clearance.
• Drug interactions: review concomitant medications for known interactions, especially immunosuppressants and CYP inducers.
• Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and light.

Lenalidomid Teva can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers: agents such as rifampin markedly reduce lenalidomide exposure.
• Anticoagulants: concurrent use may increase bleeding risk; careful monitoring required.
• Immunosuppressants: may diminish therapeutic effect or increase infection risk.

Moderate Interactions (Monitor Closely)

• P-glycoprotein substrates: potential for altered plasma levels, requiring dose adjustment.
• NSAIDs: may increase risk of renal impairment when combined.
• Vaccines: live attenuated vaccines should be avoided due to immunomodulatory effects.